186 related articles for article (PubMed ID: 18498877)
1. Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate.
Cai S; Xie Y; Bagby TR; Cohen MS; Forrest ML
J Surg Res; 2008 Jun; 147(2):247-52. PubMed ID: 18498877
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and disposition of a localized lymphatic polymeric hyaluronan conjugate of cisplatin in rodents.
Cai S; Xie Y; Davies NM; Cohen MS; Forrest ML
J Pharm Sci; 2010 Jun; 99(6):2664-71. PubMed ID: 19960530
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines.
Zhang T; Cai S; Groer C; Forrest WC; Yang Q; Mohr E; Douglas J; Aires D; Axiak-Bechtel SM; Selting KA; Swarz JA; Tate DJ; Bryan JN; Forrest ML
J Pharm Sci; 2016 Jun; 105(6):1891-1900. PubMed ID: 27155765
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer.
Xie Y; Aillon KL; Cai S; Christian JM; Davies NM; Berkland CJ; Forrest ML
Int J Pharm; 2010 Jun; 392(1-2):156-63. PubMed ID: 20363303
[TBL] [Abstract][Full Text] [Related]
5. A novel intralymphatic nanocarrier delivery system for cisplatin therapy in breast cancer with improved tumor efficacy and lower systemic toxicity in vivo.
Cohen MS; Cai S; Xie Y; Forrest ML
Am J Surg; 2009 Dec; 198(6):781-6. PubMed ID: 19969129
[TBL] [Abstract][Full Text] [Related]
6. Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugates.
Cai S; Alhowyan AA; Yang Q; Forrest WC; Shnayder Y; Forrest ML
J Drug Target; 2014 Aug; 22(7):648-57. PubMed ID: 24892741
[TBL] [Abstract][Full Text] [Related]
7. Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head & neck.
Cai S; Xie Y; Davies NM; Cohen MS; Forrest ML
Ther Deliv; 2010 Aug; 1(2):237-45. PubMed ID: 21339844
[TBL] [Abstract][Full Text] [Related]
8. [Drug concentration in axillary lymph nodes of patients with breast cancer after lymphatic chemotherapy].
Chen JH; Yang YM; Li KZ; Ling R; Yao Q; Yang H
Ai Zheng; 2005 Apr; 24(4):494-7. PubMed ID: 15820077
[TBL] [Abstract][Full Text] [Related]
9. Intratracheal Administration of Hyaluronan-Cisplatin Conjugate Nanoparticles Significantly Attenuates Lung Cancer Growth in Mice.
Ishiguro S; Cai S; Uppalapati D; Turner K; Zhang T; Forrest WC; Forrest ML; Tamura M
Pharm Res; 2016 Oct; 33(10):2517-29. PubMed ID: 27335023
[TBL] [Abstract][Full Text] [Related]
10. Exploring the Promising Potential of High Permeation Vesicle-Mediated Localized Transdermal Delivery of Docetaxel in Breast Cancer To Overcome the Limitations of Systemic Chemotherapy.
Bathara M; Date T; Chaudhari D; Ghadi R; Kuche K; Jain S
Mol Pharm; 2020 Jul; 17(7):2473-2486. PubMed ID: 32496783
[TBL] [Abstract][Full Text] [Related]
11. Phase I-II clinical trial of hyaluronan-cisplatin nanoconjugate in dogs with naturally occurring malignant tumors.
Cai S; Zhang T; Forrest WC; Yang Q; Groer C; Mohr E; Aires DJ; Axiak-Bechtel SM; Flesner BK; Henry CJ; Selting KA; Tate D; Swarz JA; Bryan JN; Forrest ML
Am J Vet Res; 2016 Sep; 77(9):1005-16. PubMed ID: 27580113
[TBL] [Abstract][Full Text] [Related]
12. Redox Responsive Hyaluronic Acid Nanogels for Treating RHAMM (CD168) Over-expressive Cancer, both Primary and Metastatic Tumors.
Yang C; Li C; Zhang P; Wu W; Jiang X
Theranostics; 2017; 7(6):1719-1734. PubMed ID: 28529647
[TBL] [Abstract][Full Text] [Related]
13. In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles.
Ganesh S; Iyer AK; Gattacceca F; Morrissey DV; Amiji MM
J Control Release; 2013 Dec; 172(3):699-706. PubMed ID: 24161254
[TBL] [Abstract][Full Text] [Related]
14. Study on intralymphatic-targeted hyaluronic acid-modified nanoliposome: influence of formulation factors on the lymphatic targeting.
Tiantian Y; Wenji Z; Mingshuang S; Rui Y; Shuangshuang S; Yuling M; Jianhua Y; Xinggang Y; Shujun W; Weisan P
Int J Pharm; 2014 Aug; 471(1-2):245-57. PubMed ID: 24858386
[TBL] [Abstract][Full Text] [Related]
15. In vivo efficacy of nano hyaluronan-conjugated cisplatin for treatment of murine melanoma.
Yang Q; Aires DJ; Cai S; Fraga GR; Zhang D; Li CZ; Forrest ML
J Drugs Dermatol; 2014 Mar; 13(3):283-7. PubMed ID: 24595572
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy.
Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB
Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609
[TBL] [Abstract][Full Text] [Related]
17. pH sensitive polymeric complex of cisplatin with hyaluronic acid exhibits tumor-targeted delivery and improved in vivo antitumor effect.
Fan X; Zhao X; Qu X; Fang J
Int J Pharm; 2015 Dec; 496(2):644-53. PubMed ID: 26529576
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of peritumoral delivery of nanoconjugated cisplatin in an in vivo murine model of head and neck squamous cell carcinoma.
Cohen SM; Rockefeller N; Mukerji R; Durham D; Forrest ML; Cai S; Cohen MS; Shnayder Y
JAMA Otolaryngol Head Neck Surg; 2013 Apr; 139(4):382-7. PubMed ID: 23599074
[TBL] [Abstract][Full Text] [Related]
19. CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases.
Li SD; Howell SB
Mol Pharm; 2010 Feb; 7(1):280-90. PubMed ID: 19994852
[TBL] [Abstract][Full Text] [Related]
20. Direct delivery of a cytotoxic anticancer agent into the metastatic lymph node using nano/microbubbles and ultrasound.
Sato T; Mori S; Sakamoto M; Arai Y; Kodama T
PLoS One; 2015; 10(4):e0123619. PubMed ID: 25897663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
